Finansavisen highlights Inify Laboratories
Norwegian financial newspaper Finansavisen highlights Inify Laboratories in a report from the laboratory in Solna. CEO Fredrik Palm and Chief Medical Officer Claes Lindh discuss challenges in healthcare, market potential and what makes Inify so unique.
The article describes how the laboratory is now fully operational and receiving patient samples in the form of prostate biopsies. These are diagnosed with the assistance of AI and a carefully controlled laboratory process, that leads to shorter, predictable waiting times for patients and high and consistent quality in the diagnostics.
Read the full article here (in Norwegian):
For further information, please contact CEO Fredrik Palm, fredrik.palm@inify.com or visit https://www.inify.com/.
About Inify Laboratories
Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system. The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.
Tags: